Cascade Pharmaceuticals emphasizes originality and focuses on differentiated innovation in drug development. The company is actively advancing multiple drug candidates targeting over 10 distinct targets. By adhering to first principles of drug development and aligning with the body's natural physiological rhythms, the team has successfully developed Linafexor, a first-in-class FXR agonist, and Thybetaxor, a potential best-in-class thyroid hormone receptor β (THRβ) agonist.
CS0159 (Linafexor) | FXR | small molecule | MASH | Global | |
---|---|---|---|---|---|
PBC | Global | ||||
PSC | Global | ||||
IBD | Global | ||||
Obesity (Combo with GLP1RA) | Global | ||||
CS060380 | THRβ | small molecule | MASH | Global | |
CS12**** | GLP1R/GIPR/GCGR | small molecule | Obesity | Global | |
T2DM | Global | ||||
CS14**** | GLP1R/GIPR/GCGR | peptide | Obesity | Global | |
T2DM | Global |